CARLO STELLA, CARMELO
CARLO STELLA, CARMELO
Dipartimento di Biotecnologie Mediche e Medicina Traslazionale
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments
2009 M. Righi, A. Giacomini, C. Lavazza, D. Sia, C. Carlo-Stella, A. Gianni
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®)
2009 C. Chiesa, F. Botta, A. Coliva, M. Maccauro, L. Devizzi, A. Guidetti, C. Carlo-Stella, E. Seregni, A.M. Gianni, E. Bombardieri
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH)
2004 C. Carlo-Stella, M. Di Nicola, R. Milani, P. Longoni, M. Milanesi, C. Bifulco, C. Stucchi, A. Guidetti, L. Cleris, F. Formelli, G. Garotta, A.M. Gianni
Amifostine (WR-2721) selective protection against melphalan genotoxicity
2000 A. Buschini, E. Anceschi, C. Carlo-Stella, E. Regazzi, V. Rizzoli, P. Poli, C. Rossi
Anticancer cell therapy with TRAIL-armed CD34+ progenitor cells
2008 C. Carlo Stella, C. Lavazza, A. Carbone, A.M. Gianni
Antitumor activity of adenovirally transduced CD34+ cells expressing membrane-bound TRAIL
2007 C. Carlo Stella, C. Lavazza, A. Carbone, A.M. Gianni
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (mTRAIL)
2006 C. Carlo-Stella, C. Lavazza, M. Di Nicola, L. Cleris, P. Longoni, M. Milanesi, M. Magni, D. Morelli, A. Gloghini, A. Carbone, A.M. Gianni
Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders
2014 M. Pierdominici, C. Barbati, M. Vomero, S.L. Locatelli, C. Carlo-Stella, E. Ortona, W. Malorni
B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY
2015 A. Roberto, L. Castagna, S. Gandolfi, V. Zanon, S. Bramanti, B. Sarina, R. Crocchiolo, E. Todisco, C. Carlo-Stella, P. Tentorio, I. Timofeeva, A. Santoro, S. Della Bella, M. Roederer, D. Mavilio, E. Lugli
Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi
2014 A. Anastasia, C. Carlo-Stella, P. Corradini, F. Salvi, C. Rusconi, A. Pulsoni, S. Hohaus, P. Pregno, S. Viviani, E. Brusamolino, S. Luminari, L. Giordano, A. Santoro
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma : Final results of a multicenter phase II study
2016 A. Santoro, R. Mazza, A. Pulsoni, A. Re, M. Bonfichi, V.R. Zilioli, F. Salvi, F. Merli, A. Anastasia, S. Luminari, G. Annechini, M. Gotti, A. Peli, A.M. Liberati, N. Di Renzo, L. Castagna, L. Giordano, C. Carlo Stella
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts
2014 S.L. Locatelli, L. Cleris, G. Stirparo, S. Tartari, E. Saba, M. Pierdominici, W. Malorni, A. Carbone, A. Anichini, C. Carlo-Stella
Biology and clinical applications of marrow mesenchymal stem cells
2005 C. Carlo-Stella, A.M. Gianni
Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells
2002 A. Buschini, C. Alessandrini, A. Martino, L. Pasini, V. Rizzoli, C. Carlo Stella, P. Poli, C. Rossi
Bone Marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide
2014 L. Castagna, R. Crocchiolo, S. Furst, S. Bramanti, J. El Cheikh, B. Sarina, A. Granata, E. Mauro, C. Faucher, B. Mohty, S. Harbi, C. Chabannon, C. Carlo-Stella, A. Santoro, D. Blaise
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a phase I trial in metastatic melanoma
2004 M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, N. Cascinelli, G. Parmiani, A. Gianni, A. Anichini
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation : results from a named patient program at four Italian centers
2015 C. Carlo-Stella, F. Ricci, S.E. Dalto, R. Mazza, M. Malagola, F. Patriarca, S. Viviani, D. Russo, L. Giordano, L. Castagna, P. Corradini, A. Santoro
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice
2006 C. Carlo-Stella, A. Guidetti, M. Di Nicola, P. Longoni, L. Cleris, C. Lavazza, M. Milanesi, R. Milani, M. Carrabba, L. Farina, F. Formelli, A.M. Gianni, P. Corradini
Cellule staminali emopoietiche
2007 C. Carlo Stella
Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma
2018 V. Spina, A. Bruscaggin, A. Cuccaro, M. Martini, M. Di Trani, G. Forestieri, M. Manzoni, A. Condoluci, A. Arribas, L. Terzi-Di-Bergamo, S.L. Locatelli, E. Cupelli, L. Ceriani, A.A. Moccia, A. Stathis, L. Nassi, C. Deambrogi, F. Diop, F. Guidetti, A. Cocomazzi, S. Annunziata, V. Rufini, A. Giordano, A. Neri, R. Boldorini, B. Gerber, F. Bertoni, M. Ghielmini, G. Stüssi, A. Santoro, F. Cavalli, E. Zucca, L.M. Larocca, G. Gaidano, S. Hohaus, C. Carlo-Stella, D. Rossi